Pentasa Prolonged Release Tablet 500mg

Šalis: Malaizija

kalba: anglų

Šaltinis: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

Veiklioji medžiaga:

5-AMINO SALICYLIC ACID(5-ASA),MESALAZINE

Prieinama:

Ferring Sdn. Bhd.

INN (Tarptautinis Pavadinimas):

5-AMINO SALICYLIC ACID(5-ASA),MESALAZINE

Vienetai pakuotėje:

100Tablet Tablets; 100 Tablets

Pagaminta:

Ferring International Center SA

Pakuotės lapelis

_CONSUMER MEDICATION INFORMATION LEAFLET (RIMUP)_
_ _
_ _
PENTASA
®
PROLONGED RELEASE TABLETS
Mesalazine 500mg and 1g
1
WHAT IS IN THIS LEAFLET:
1.
What Pentasa is used for
2.
How Pentasa works
3.
Before you take Pentasa
4.
How to take Pentasa
5.
While you are taking Pentasa
6.
Side effects
7.
Storage and disposal of Pentasa
8.
Product description
9.
Manufacturer and Product
Registration Holder
10.
Date of Revision
1.
WHAT PENTASA IS USED FOR
Pentasa Prolonged Release Tablets are
used to treat mild to moderate
ulcerative colitis (an inflammation
condition of the gut) and Crohn’s
disease (a condition that causes
inflammation of the wall of the gut.
Any part of the gut can be affected).
2.
HOW PENTASA WORKS
PENTASA contains the active
ingredient m
_esalazine. _
The prolonged
release tablets release the active
ingredient slowly which then acts
locally to reduce the inflammation and
help relieve or stop the pain.
3.
BEFORE YOU TAKE PENTASA
_When you must not use it: _
DO NOT take Pentasa
•
If you are allergic to mesalazine,
salicylates or any of the other
ingredients of Pentasa (listed in
ingredients section)
•
If you have severe liver or kidney
problem
If this applies to you, do not take
Pentasa and tell your doctor
immediately.
_Before you start to use it: _
Warning and precautions
•
Tell your doctor or pharmacist if
you have or have had any of the
following conditions:
-
Intolerant or hypersensitive to
sulphasalazine
- With impaired liver function
- With kidney impairment
- With lung disease, in particular
asthma.
Mesalazine-induced cardiac
hypersensitivity reactions (myo- and
pericarditis) have been reported rarely.
Serious blood dyscrasias have been
reported very rarely with mesalazine.
Blood test for differential blood count
is recommended prior to and during
treatment, at the discretion of the
treating physician.
Concomitant treatment with mesalazine
can increase the risk of blood dyscrasia
in patients receiving azathioprine, or 6-
mercaptopurine or thioguanine.
Treatment should be discontinued on
sus